Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.79 |
| ▸ | CNR1 | P21554 | 7/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canbisol SCHEMBL2109878 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL11742031 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL11734297 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL31545994 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL11737376 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL23602227 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL11728974 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL17414499 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL2109880 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Canbisol SCHEMBL27448557 | 1.00 | CNR2 (0.79) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642449-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NABILONE FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | Adtech Pharma, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145493-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NABILONE FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | ADTECH PHARMA, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145493-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NABILONE FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | ADTECH PHARMA, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR2 3/4885CNR1 1/4885NR1I2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.